S1222
Clinical - Urology
ESTRO 2026
Results: A total of 256 patients were enrolled across 17 French centers between 12/2018 and 05/2023. The safety population included 127 patients in arm A and 121 in arm B (8 patients were excluded as they did not receive ENRT). Prior prostate or prostatic bed irradiation was reported in 57% and 55% of patients, respectively. In arm B, 39 patients also received paraaortic irradiation. At 6 months, grade ≥ 2 genitourinary (GU) and gastrointestinal (GI) toxicities occurred in 2.4% vs 9.9% (p=0.02) and 0% vs 19.8% (p<0.001) of patients in arms A and B, respectively. At 18 months, GU toxicity was 4.1% vs 10.7%, (p=0.04) in arms A and B, respectively, while no difference in GI toxicity was observed. Prior prostate or prostatic bed irradiation did not increase toxicity at any time point. Among patients receiving paraaortic irradiation, compared to those without : grade ≥ 2 toxicity was similar at 6 months (GU: 8.5% vs 12.8%, p=0.8; GI: 19.5% vs 20.5%, p=0.9), or at 18 months (GU: 20.5% vs 23.2%, p=0.74; GI: 0% vs 6.1% ), though 6 months upper grade ≥ 1 GI disorders were more frequent (25.6% vs 9.8%, p=0.02). Conclusion: Eighteen-month toxicity of salvage ENRT with a simultaneous boost to the pathologic pelvic and/or paraaortic lymphnodes, associated with 6-months ADT was acceptable, even among patients with prior prostate irradiation or additional paraaortic irradiation (NCT03630666- RCB 2018-A00551-54; Funding PHRC-K 16-129). Keywords: oligometastases, pelvic node, SBRT Stereotactic Ablative Radiotherapy (SAR-PROST) for localized prostate cancer: updated outcomes and extended follow-up of 32 Gy in four fractions Ines Ollinger 1 , Julia García 1 , Oscar Muñoz 1 , Blas David Delgado 1 , Sara Estrella 2 , Patricia Cabrera 1 1 Radiation Oncology, Hopistal Universitario Virgen del Rocio, Seville, Spain. 2 Radiation Oncology, Hospital Virgen del Puerto, Plasencia, Spain Purpose/Objective: We previously reported preliminary results of the SAR- PROST trial evaluating stereotactic body radiotherapy (SBRT) with 32 Gy in four fractions for localized prostate cancer. Here we present updated data with extended follow-up and additional patients, focusing on long-term safety, biochemical control, and feasibility. Material/Methods: This phase I/II prospective study included patients with low- to intermediate-risk localized prostate cancer treated with SBRT (32 Gy in four fractions, two Digital Poster 2289
Proffered Paper 2263 Early Toxicity of elective nodal RT for
Oligorecurrent Pelvic/Paraaortic nodes in Prostate Cancer: a randomised phase 3 trial OLIGOPELVIS- 2/GETUG P12. Hugo Corda 1 , Audrey Blanc-Lapierre 2 , Grégoire Pigné 3 , Lysian Cartier 4 , David Pasquier 5 , Philippe Ronchin 6 , Guillaume Bera 7 , Ali Hasbini 8 , Benjamin Schipman 9 , Jonathan Khalifa 10 , Paul Sargos 11 , Magali Quivrin 12 , Ulrike Schick 13 , Frédéric Mallet 14 , Cécile Laude 15 , Clotilde Morand 16 , Genevieve Loos 17 , Nathalie Mesgouez-Nebout 1 , Stéphane Supiot 18 1 Radiation oncology, ICO, Angers, France. 2 Statistics, ICO, Nantes, France. 3 Radiation oncology, CHU, St- Etienne, France. 4 Radiation oncology, ISC, Avignon, France. 5 Radiation oncology, COL, Lille, France. 6 Radiation oncology, CAC, Mougins, France. 7 Radiation oncology, CH, Lorient, France. 8 Radiation oncology, Clinique Pasteur, Brest, France. 9 Radiation oncology, ICB, Dijon, France. 10 Radiation oncology, Oncopole, Toulouse, France. 11 Radiation oncology, Institut Bergonié, Bordeaux, France. 12 Radiation oncology, CGFL, Dijon, France. 13 Radiation oncology, CHU, Brest, France. 14 Radiation oncology, ICC, Reims, France. 15 Radiation oncology, CLB, Lyon, France. 16 Radiation oncology, CH, La Roche-sur-Yon, France. 17 Radiation oncology, CJP, Clermont-Ferrand, France. 18 Radiation oncology, ICO, Nantes, France Purpose/Objective: Limited pelvic/paraaortic nodal relapse of prostate cancer after radical local treatment remains a major challenge for locoregional salvage strategies. Salvage Elective Nodes radiotherapy (ENRT) is an appealing option, but concerns persist regarding its toxicity. This study evaluates the 18-month toxicity profile of salvage ENRT combined with 6-months androgen deprivation therapy (ADT) in patients with pelvic and/or paraaortic oligometastatic disease, compared with ADT alone. Material/Methods: OLIGOPELVIS-2/GETUG P12was a prospective, multicenter, randomized phase III trial. Patients were randomized 1:1 to arm A (ADT alone) or arm B (ADT + ENRT: 54 Gy/1.8 Gy per fraction to the pelvic lymphnodes and 66 Gy/2.2 Gy per fraction to pathologic nodes). ENRT started after three months of
ADT. After analyzing relapse patterns in the OLIGOPELVIS 1 study, a December 22, 2021
amendment permitted the inclusion of paraaortic lymphnodes and extended irradiation fields up to the renal arteries. The primary outcome was progression- free survival, defined as the time from randomization until biochemical-clinical failure or death from any cause. Here we present early toxicity results defined using NCI-CTCAE v4.0.
Made with FlippingBook - Share PDF online